Athenagen buys Osprey Pharmaceutical
Executive Summary
Athenagen (small-molecule angiogenesis modulators) has agreed to buy all assets of Osprey Pharmaceutical Co. (University of Florida spin-off; neurological diseases).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Intra-Biotech Deal
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice